Becton Dickinson and Company ($BDX) Stock Forecast: Up 2.8% Today

What is Becton Dickinson and Company?

BDX (Becton, Dickinson and Company) is a leading medical technology company specializing in medication management technologies and infusion systems. The company is dedicated to improving patient safety and clinical efficiency through connected care solutions.

Why is Becton Dickinson and Company going up?

BDX stock is up 2.8% on Feb 4, 2026 15:43

• BDX saw a notable increase in its stock price today, following the reception of three 2026 Best in KLAS Awards for its medication management technologies. These awards underscore the company's industry leadership and positive feedback from healthcare professionals.
• The strategic decision by Becton, Dickinson and Company to restructure its business by spinning off its Biosciences & Diagnostic Solutions division and merging it with Waters Corporation likely contributed to investor confidence and propelled the stock price upwards.
• Despite Mediolanum International Funds Ltd reducing its holdings in BDX, other institutional investors making adjustments to their positions did not detract from the overall positive outlook on the company.
• Analysts raised the price target for BDX, emphasizing upcoming segment transitions and the company's investments in expanding production capabilities, which further bolstered investor confidence in the stock's future growth prospects.

BDX Price Chart

BDX Technical Analysis

BDX News

BD Extends Leadership in Connected Medication Management Winning Three 2026 Best in KLAS Awards

BD (Becton, Dickinson and Company) announced it won three 2026 Best in KLAS Awards for its medication management technologies, including BD Pyxis™ MedStation™ ES for Automated Dispensing Cabinets and the BD Alaris™ Infusion System for both Traditional and EHR-Integrated Smart Pumps. These awards reflect positive feedback from healthcare professionals and underscore BD's commitment to connected care, aiming to enhance patient safety and clinical efficiency through integrated dispensing, infusion, and data intelligence.

https://news.bd.com/2026-02-04-BD-Extends-Leadership-in-Connected-Medication-Management-Winning-Three-2026-Best-in-KLAS-Awards

Mediolanum International Funds Ltd Sells 43,988 Shares of Becton, Dickinson and Company $BDX

Mediolanum International Funds Ltd significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 94.4% in the third quarter, selling 43,988 shares and retaining 2,616 shares valued at $481,000. Other institutional investors like Brighton Jones LLC, RiverGlades Family Offices LLC, Transcend Capital Advisors LLC, Belpointe Asset Management LLC, and Strs Ohio made various adjustments to their BDX holdings. The article also details recent insider trades, analyst ratings, and the company's financial performance, including a stock repurchase program and dividend announcement.

https://www.marketbeat.com/instant-alerts/filing-mediolanum-international-funds-ltd-sells-43988-shares-of-becton-dickinson-and-company-bdx-2026-02-04/

Abbott Laboratories Stock Now 18% Cheaper, Time To Buy

Abbott Laboratories (ABT) stock is presented as a compelling buy opportunity, currently 18% cheaper based on its Price-to-Sales ratio compared to a year ago. The company demonstrates strong fundamentals including high operating cash flow and operating margins, especially in its Medical Devices segment, with new product launches expected to reaccelerate other areas. Despite past market drawdowns, ABT is highlighted for its consistent profitability and cash generation capacity, making it attractive for long-term investors seeking discounted quality.

https://www.trefis.com/stock/abt/articles2/589567/abbott-laboratories-stock-now-18-cheaper-time-to-buy/2026-02-04

Becton Dickinson Reshapes Portfolio With Spin Off AI And Sustainability Focus

Becton Dickinson (NYSE:BDX) plans to spin off its Biosciences & Diagnostic Solutions business and merge it with Waters Corporation via a Reverse Morris Trust. This strategic move aims to separate BD's research tools and diagnostics from its core medical technology. The company is also introducing AI-driven platforms and sustainability programs to recycle medical plastics, while its stock has seen mixed performance but a recent positive short-term return.

https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-reshapes-portfolio-with-spin-off-ai-and-sus

Piper Sandler Highlights Upcoming Segment Transition at Becton Dickinson (BDX)

Piper Sandler recently raised its price target for Becton, Dickinson and Company (BDX) to $205, maintaining a Neutral rating. This adjustment aligns with BDX's upcoming change in reporting business units starting Q1 2026, which will see the Life Sciences segment transition to Waters. Additionally, BDX is investing $110 million to expand prefillable syringe production in the U.S. to support the delivery of biologic and GLP-1 drugs.

https://finviz.com/news/297239/piper-sandler-highlights-upcoming-segment-transition-at-becton-dickinson-bdx

Trending Today

Bittensor ($TAO) Crypto Forecast: Down 5.2% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 5.2% Today

Under Armour Inc. Class A ($UAA) Stock Forecast: Up 5.0% Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Up 5.2% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Up 5.8% Today

Unity Software ($U) Stock Forecast: Up 6.5% Today

Amphenol Corporation ($APH) Stock Forecast: Up 5.4% Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

MicroStrategy ($MSTR) Stock Forecast: Up 8.6% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.0% Today

Becton Dickinson and Company Price History

05.00.2026 - BDX Stock was up 1.9%

• BDX experienced a strong bullish movement today, likely driven by positive developments.
• A major financial institution raised the price target for BDX shares, indicating confidence in the company's performance and potential upside.
• Recent innovations and advancements such as the first Phasix™ Mesh laparotomy reinforcement case in Greece and progress in the PREVENT clinical trial showcase BD's dedication to improving patient outcomes, potentially contributing to positive investor sentiment.
• An additional $10 million share repurchase program was announced, signaling the company's confidence in its financial position and commitment to returning capital to shareholders, which may have bolstered investor confidence in BDX.

01.04.2025 - BDX Stock was down 10.3%

• Despite delivering earnings and revenue surprises in Q2, Becton Dickinson (BDX) experienced a bearish movement in its stock.
• Investors may have been anticipating stronger performance from the company, leading to a sell-off post earnings report.
• The market's negative reaction to projections for key metrics suggests concerns about the company's future growth prospects.
• Overall, the bearish movement in BDX could stem from profit-taking by investors expecting more robust results.

01.04.2025 - BDX Stock was down 14.7%

• BDX posted strong Q1 adjusted EPS, surpassing expectations, but fell short of sales forecasts, causing a negative market response.
• The company's commitment to invest $2.5 billion in enhancing US manufacturing raised concerns about potential cost increases and impacts on future profitability.
• The reduction in fiscal 2025 EPS guidance, attributed to a $0.25 tariff impact, likely influenced investor sentiment negatively.
• Despite outperforming expectations in Q2 earnings, adjustments in overall outlook and guidance appeared to dampen investor enthusiasm, leading to a decline in the stock price.

02.04.2025 - BDX Stock was down 5.0%

• The stock of Becton Dickinson (BDX) experienced a strong bearish movement.
• The potential tariff impact on the company's profit outlook for 2025, coupled with a cut in EPS guidance due to tariff hits, likely contributed to the negative market sentiment.
• Despite posting Q2 earnings that topped estimates, the missed revenue consensus and reduced EPS guidance may have overshadowed the positive earnings surprise, leading to the bearish trend.
• The technical analysis suggesting a possible capitulation in BDX could have added to the selling pressure on the stock as investors reacted to the mixed financial performance and future outlook.

02.04.2025 - BDX Stock was down 8.1%

• BDX stock displayed bearish movement on the market recently.
• Concerns about potential tariff impact on BDX's 2025 profit outlook, leading to a $0.25 decrease in EPS guidance, might have influenced the bearish sentiment.
• Despite exceeding Q2 earnings expectations, BDX fell short of sales consensus and adjusted its EPS guidance, disappointing investors and driving the bearish trend.
• Technical analysis hints at a possible capitulation in BDX, adding to the negative market sentiment and contributing to the stock's decline.

04.01.2026 - BDX Stock was up 2.8%

• BDX saw a notable increase in its stock price today, following the reception of three 2026 Best in KLAS Awards for its medication management technologies. These awards underscore the company's industry leadership and positive feedback from healthcare professionals.
• The strategic decision by Becton, Dickinson and Company to restructure its business by spinning off its Biosciences & Diagnostic Solutions division and merging it with Waters Corporation likely contributed to investor confidence and propelled the stock price upwards.
• Despite Mediolanum International Funds Ltd reducing its holdings in BDX, other institutional investors making adjustments to their positions did not detract from the overall positive outlook on the company.
• Analysts raised the price target for BDX, emphasizing upcoming segment transitions and the company's investments in expanding production capabilities, which further bolstered investor confidence in the stock's future growth prospects.

06.01.2025 - BDX Stock was down 5.1%

• BDX posted impressive Q1 earnings, surpassing revenue and EPS expectations, indicating a strong performance in the last quarter.
• Despite the favorable earnings, the market responded negatively to BDX revising its forecast and revealing plans to split its Biosciences and Diagnostic Solutions business segments.
• Investors may have apprehensions regarding the consequences of this strategic decision and its potential effects on future growth and profitability, influencing the bearish market trend seen in BDX today.

07.07.2025 - BDX Stock was up 7.4%

• BDX stock experienced a strong bullish movement today.
• The company surpassed Q3 earnings and revenue estimates, indicating strong financial performance.
• Despite expectations of declining earnings, BDX managed to deliver positive surprises, boosting investor confidence.
• The better-than-expected performance in key metrics for the quarter ended June 2025 likely contributed to the bullish market movement.

06.10.2025 - BDX Stock was down 0.8%

• Despite surpassing expectations for earnings and revenue in the quarter, BDX witnessed a decline in its stock value.
• The market's reaction might be linked to uncertainties regarding the company's future growth trajectory or provided guidance.
• Investors could be considering broader factors like global economic conditions or developments within the industry, impacting the stock's downward trend.
• The bearish movement could also be influenced by profit-taking activities or prevailing market sentiment, potentially overshadowing the positive earnings outcome.

25.08.2025 - BDX Stock was down 3.9%

• The bearish movement in BDX stock could be attributed to profit-taking by investors after a recent bullish run.
• The initiation of coverage on Biogen (NASDAQ: BIIB) on a bullish note may have diverted attention and funds away from BDX temporarily.
• Market analysts changing their outlook on top names could have influenced investor sentiment towards BDX, leading to the bearish movement.
• Overall, the market movement in BDX today may be a short-term correction influenced by external factors rather than any fundamental issues with the company itself.

23.00.2026 - BDX Stock was down 5.0%

• BDX faced a bearish market movement despite positive third-quarter results, increased dividend, and strong FY2026 EPS guidance.
• The sale of SmartDose rights by a pharmaceutical services company to another entity could have impacted BDX's market sentiment negatively, leading to the bearish movement.
• The launch of BD Research Cloud 7.0 with AI-powered tools for immunology and cancer research, while positive for BD's long-term growth, might not have been enough to offset the overall market sentiment impacting the stock price.
• Investors may have reacted cautiously to the news, potentially waiting for more clarity on how these developments will translate into revenue growth and market competitiveness for BDX in the future.

10.11.2025 - BDX Stock was up 2.8%

• An investment firm increased Becton Dickinson's price target to $220 from $215 and maintained a Buy rating, citing positive implications from a transaction with Waters Corporation. This adjustment reflects optimism about the company's future performance.
• The global Pharmacy Automation Systems Market is projected to grow significantly, with key players like BD poised to benefit from the increasing adoption of automation in healthcare.
• Solventum Corporation, a healthcare company spun off from 3M, is garnering attention for its potential turnaround story, which could indirectly impact positively on companies like Becton, Dickinson and Co.
• Despite a reduction in stake by Natixis, institutional investors still hold a significant portion of Becton, Dickinson and Co.'s stock, indicating continued confidence in the company's prospects.